Cargando…

Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours

BACKGROUND: It is well known that sarcopenia is a common risk factor in patients with gastrointestinal tumours, which may negatively affect the clinical outcome and prognosis. Recent studies suggest that serum creatinine-cystatin C (Cr/CysC) ratio may be associated with sarcopenia, but this associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Ping’an, Guo, Honghai, Sun, Chenyu, Chen, Shuya, Yang, Peigang, Tian, Yuan, Lowe, Scott, Zhao, Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478187/
https://www.ncbi.nlm.nih.gov/pubmed/36118766
http://dx.doi.org/10.3389/fnut.2022.963265
_version_ 1784790512773890048
author Ding, Ping’an
Guo, Honghai
Sun, Chenyu
Chen, Shuya
Yang, Peigang
Tian, Yuan
Lowe, Scott
Zhao, Qun
author_facet Ding, Ping’an
Guo, Honghai
Sun, Chenyu
Chen, Shuya
Yang, Peigang
Tian, Yuan
Lowe, Scott
Zhao, Qun
author_sort Ding, Ping’an
collection PubMed
description BACKGROUND: It is well known that sarcopenia is a common risk factor in patients with gastrointestinal tumours, which may negatively affect the clinical outcome and prognosis. Recent studies suggest that serum creatinine-cystatin C (Cr/CysC) ratio may be associated with sarcopenia, but this association lacks sufficient evidence in patients with gastrointestinal stromal tumours (GIST). Therefore, this study aimed to investigate whether the Cr/CysC ratio was associated with sarcopenia and recurrence-free survival (RFS) in patients with GIST. MATERIALS AND METHODS: The study retrospectively analysed 413 patients with GIST who underwent surgical resection from January 2016 to January 2020. The serum Cr/CysC ratio was determined as a proxy for sarcopenia by comparing it with various biomarkers and Cox multifactorial analysis was used to determine the relationship between Cr/CysC ratio and prognosis. RESULTS: Serum Cr/CysC was positively correlated with skeletal muscle area (SMA) (r = 0.256, p < 0.001), skeletal muscle index (SMI) (r = 0.300, p < 0.001), and hand grip strength (HGS) (r = 0.251, p < 0.001). The area under the receiver operator characteristic curve for sarcopenic subjects with serum Cr/CysC ratio was significantly greater than other biomarkers (Cr/CysC: 0.840, CysC: 0.732, Cr: 0.518). The optimal cut-off value for Cr/CysC was 0.65, and patients in the high Cr/CysC group had a higher 3-year recurrence-free survival (RFS) than those in the low Cr/CysC group (92.72 vs. 72.46%, p < 0.001). Cox multifactorial analysis found that the Cr/CysC ratio was an independent risk factor for RFS in GIST patients (HR = 2.143, 95% CI: 1.431–5.459, p = 0.011). CONCLUSION: Serum Cr/CysC ratio has satisfactory and comparable diagnostic accuracy, and prognostic value for sarcopenia in patients with GIST. Therefore, it can be a simple and practical clinical tool to screen sarcopenia in GIST patients. However, further studies are required to validate these findings.
format Online
Article
Text
id pubmed-9478187
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94781872022-09-17 Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours Ding, Ping’an Guo, Honghai Sun, Chenyu Chen, Shuya Yang, Peigang Tian, Yuan Lowe, Scott Zhao, Qun Front Nutr Nutrition BACKGROUND: It is well known that sarcopenia is a common risk factor in patients with gastrointestinal tumours, which may negatively affect the clinical outcome and prognosis. Recent studies suggest that serum creatinine-cystatin C (Cr/CysC) ratio may be associated with sarcopenia, but this association lacks sufficient evidence in patients with gastrointestinal stromal tumours (GIST). Therefore, this study aimed to investigate whether the Cr/CysC ratio was associated with sarcopenia and recurrence-free survival (RFS) in patients with GIST. MATERIALS AND METHODS: The study retrospectively analysed 413 patients with GIST who underwent surgical resection from January 2016 to January 2020. The serum Cr/CysC ratio was determined as a proxy for sarcopenia by comparing it with various biomarkers and Cox multifactorial analysis was used to determine the relationship between Cr/CysC ratio and prognosis. RESULTS: Serum Cr/CysC was positively correlated with skeletal muscle area (SMA) (r = 0.256, p < 0.001), skeletal muscle index (SMI) (r = 0.300, p < 0.001), and hand grip strength (HGS) (r = 0.251, p < 0.001). The area under the receiver operator characteristic curve for sarcopenic subjects with serum Cr/CysC ratio was significantly greater than other biomarkers (Cr/CysC: 0.840, CysC: 0.732, Cr: 0.518). The optimal cut-off value for Cr/CysC was 0.65, and patients in the high Cr/CysC group had a higher 3-year recurrence-free survival (RFS) than those in the low Cr/CysC group (92.72 vs. 72.46%, p < 0.001). Cox multifactorial analysis found that the Cr/CysC ratio was an independent risk factor for RFS in GIST patients (HR = 2.143, 95% CI: 1.431–5.459, p = 0.011). CONCLUSION: Serum Cr/CysC ratio has satisfactory and comparable diagnostic accuracy, and prognostic value for sarcopenia in patients with GIST. Therefore, it can be a simple and practical clinical tool to screen sarcopenia in GIST patients. However, further studies are required to validate these findings. Frontiers Media S.A. 2022-09-02 /pmc/articles/PMC9478187/ /pubmed/36118766 http://dx.doi.org/10.3389/fnut.2022.963265 Text en Copyright © 2022 Ding, Guo, Sun, Chen, Yang, Tian, Lowe and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Ding, Ping’an
Guo, Honghai
Sun, Chenyu
Chen, Shuya
Yang, Peigang
Tian, Yuan
Lowe, Scott
Zhao, Qun
Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours
title Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours
title_full Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours
title_fullStr Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours
title_full_unstemmed Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours
title_short Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours
title_sort serum creatinine/cystatin c ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478187/
https://www.ncbi.nlm.nih.gov/pubmed/36118766
http://dx.doi.org/10.3389/fnut.2022.963265
work_keys_str_mv AT dingpingan serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours
AT guohonghai serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours
AT sunchenyu serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours
AT chenshuya serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours
AT yangpeigang serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours
AT tianyuan serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours
AT lowescott serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours
AT zhaoqun serumcreatininecystatincratioisasystemicmarkerofsarcopeniainpatientswithgastrointestinalstromaltumours